iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/21867926/
CD8(+) T cells: foot soldiers of the immune system - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug 26;35(2):161-8.
doi: 10.1016/j.immuni.2011.07.010.

CD8(+) T cells: foot soldiers of the immune system

Affiliations
Review

CD8(+) T cells: foot soldiers of the immune system

Nu Zhang et al. Immunity. .

Abstract

Resting naive CD8(+) T cells have an astounding capacity to react to pathogens by massive expansion and differentiation into cytotoxic effector cells that migrate to all corners of the body to clear the infection. The initial interaction with antigen-presenting cells in the central lymphoid organs drives an orchestrated program of differentiation aimed at producing sufficient numbers of effectors to get the job done without resulting in clonal exhaustion. Interactions with antigen-presenting cells and other immune cells continue at the site of infection to regulate further on-site expansion and differentiation, all with the goal of protecting the host with minimal bystander tissue damage. Here we review recent advances in CD8(+) T cell recognition of antigen in lymphoid as well as in nonlymphoid tissues in the periphery, and how CD8(+) T cell expansion and differentiation are controlled in these contexts.

PubMed Disclaimer

Figures

Figure 1
Figure 1
IL-2- and Blimp-1-Dependent Effector CD8+ T Cell Differentiation After antigen priming, activated CD8+ T cells receive signals from multiple cytokines such as IL-2, IL-21, Il-12, and Il-27. IL-2 signaling induces Blimp-1 expression which cooperates with other transcription factors to promote CD8+ (CTL) T cell effector differentiation, migration to the peripheral sites during acute infection, and exhaustion during chronic infection while inhibiting MPEC and Tcm cell differentiation.
Figure 2
Figure 2
Self-Control by Effector CD8+ T Cells In infected peripheral tissues, some effector CD8+ (CTL) T cells receive additional local signals including antigen, CD4+ T cell-derived IL-2, and innate cell-derived IL-27, and transiently acquire the ability to secrete IL-10 in a Blimp-1-dependent manner. CTL-derived IL-10 is critical to control local inflammation and tissue damage.

Similar articles

Cited by

References

    1. Apetoh L., Quintana F.J., Pot C., Joller N., Xiao S., Kumar D., Burns E.J., Sherr D.H., Weiner H.L., Kuchroo V.K. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 2010;11:854–861. - PMC - PubMed
    1. Bachmann M.F., Wolint P., Walton S., Schwarz K., Oxenius A. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur. J. Immunol. 2007;37:1502–1512. - PubMed
    1. Badovinac V.P., Haring J.S., Harty J.T. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. Immunity. 2007;26:827–841. - PMC - PubMed
    1. Bajénoff M., Egen J.G., Koo L.Y., Laugier J.P., Brau F., Glaichenhaus N., Germain R.N. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity. 2006;25:989–1001. - PMC - PubMed
    1. Bartholdy C., Christensen J.E., Grujic M., Christensen J.P., Thomsen A.R. T-cell intrinsic expression of MyD88 is required for sustained expansion of the virus-specific CD8+ T-cell population in LCMV-infected mice. J. Gen. Virol. 2009;90:423–431. - PubMed

Substances